(Albany, USA) DelveInsight’s, “T-Cell Lymphoma Pipeline Insight, 2023” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in T-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To know more about T-Cell Lymphoma pipeline report, click here @ T-Cell Lymphoma Drugs in different phases
Some facts of the T-Cell Lymphoma Pipeline report are:
Request for a sample to know more about the T-Cell Lymphoma clinical trial advancements @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight
T-Cell Lymphoma Overview:
T cell lymphomas (TCL) are a very heterogeneous group of lymphoid malignancies derived from mature T cells differing by localization, pathological features, and clinical presentation. T-Cell Lymphomas can develop in lymphoid tissues such as the lymph nodes and spleen or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others).
T-Cell Lymphoma Emerging Drugs
SP-02: Solasia Pharma
SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, darinaparsin demonstrated clinical activity evidence in lymphoma, particularly PTCL. Furthermore, the Phase I study done in the US and the Pan-Asian Phase 1 study demonstrated positive efficacy and safety of SP-02. The drug is currently being evaluated in Phase III clinical trials to treat patients with Peripheral T Cell Lymphoma. Solasia has begun preparing for the NDA Filing of SP-02.
CC-486: Celgene
CC-486 (Azacitidine) is an orally-active form of Vidaza, a chemical analog of the cytosine nucleoside used in DNA and RNA. The main mechanism of action is thought to be hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. CC-486 is indicated for the treatment of acute myeloid leukemia in first remission. The drug is in Phase III clinical studies for the treatment of T-Cell Lymphoma.
Request for a sample to get detailed analysis of T-Cell Lymphoma therapies, click here@ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight
T-Cell Lymphoma Pipeline Therapeutic Assessment
There are approx. 85+ key companies which are developing the therapies for T-Cell Lymphoma. The companies which have their T-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Solasia Pharma and others.
Scope of the T-Cell Lymphoma Pipeline Report
Learn more about the emerging T-Cell Lymphoma pipeline therapies @ T-Cell Lymphoma Clinical Trials Analysis – https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight
Table of Content
Introduction
Executive Summary
T-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Pre-registration)
Geptanolimab: Genor Biopharma
Drug profiles in the detailed report…..
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
IMC-001: ImmuneOncia Therapeutics
Early Stage Products (Phase I/II)
Tolinapant: Astex Pharmaceuticals
Early Stage Products (Phase I)
TTI-621: Trillium Therapeutics
Preclinical and Discovery Stage Products
BBI 3000: Brickell Biotech Inc
Inactive Products
T-Cell Lymphoma Key Companies
T-Cell Lymphoma Key Products
T-Cell Lymphoma- Unmet Needs
T-Cell Lymphoma- Market Drivers and Barriers
T-Cell Lymphoma- Future Perspectives and Conclusion
T-Cell Lymphoma Analyst Views
Appendix
Request for free sample @ https://www.delveinsight.com/sample-request/t-cell-lymphoma-pipeline-insight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting